GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis

GlaxoSmithKline (GSK)

Status and phase

Terminated

Phase 1

Conditions

Ulcerative Colitis

Treatments

Drug: GI-270384

Study type

Interventional

Funder types

Industry

Identifiers

NCT00457171

EBD100729

Details and patient eligibility

About

The aim of this double blind, placebo controlled, study is to evaluate activity consistent with efficacy provided by 14 days administration of GI270384X, and to provide preliminary pharmacokinetics and safety/tolerability of 14 days administration of GI270384X in patients with mild to moderate active ulcerative colitis (UC).

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Females can be of childbearing or non-childbearing potential
Subjects who have relapsing (relapsed = 6 weeks ago; this being at least a second episode) mild to moderate UC (score of 4 - 11 on the MTWI at Screening and with an endoscopy score of = 2). Diagnosis of UC originally must be established by sigmoidoscopy or colonoscopy, and have compatible histology.
As confirmed through signed informed consent, the subject must understand and be able, willing and likely to fully comply with study procedures and restrictions

Exclusion criteria

Subjects with severe UC according to the MTWI (score >11) and subjects who have been in relapse for > 6 weeks.
Subjects are not eligible for this study if they have Crohn's Disease, proctitis (where the extent of inflammation = 15 cm), bleeding disorders, or active ulcer disease.
Positive stool culture for enteric pathogens (including Salmonella, Shigella, Yersinia, Aeromonas, Plesiomonas or Campylobacter).
Presence of Clostridium difficile toxin present or with ova or parasites as detected by microscopy.